FOLH1 and prostate carcinoma: In a study evaluating the biodistribution and pharmacokinetics of [68Ga]Ga-PSMA-617 in prostate cancer patients, Afshar-Oromieh et al. [10] demonstrated that [68Ga]Ga-PSMA-617 has lower accumulation into normal organs (including the liver) and slower pharmacokinetics than [68Ga]Ga-PSMA-11, resulting in better lesion contrast and tracer accumulation at 3 h post-injection, rather than at 1 h post-injection.